Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion
UWFARVO
1 other identifier
observational
60
1 country
1
Brief Summary
The changes of ischemic index and vascular leakage index, and the effect on macular edema and neovascularization in retinal vein occlusion by ultra-wide field fluorescence angiography (UWFA)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 29, 2019
CompletedFirst Posted
Study publicly available on registry
September 3, 2019
CompletedStudy Start
First participant enrolled
September 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 12, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 12, 2025
CompletedOctober 18, 2023
October 1, 2023
5.2 years
August 29, 2019
October 17, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in non-perfused areas in different retinal area
Change in non-perfused areas in different retinal area from Baseline to 1，2，3，6，9and 12 months
Baseline and1，2，3，6，9and 12 months
Secondary Outcomes (2)
Change in best corrected visual acuity
Baseline and1，2， 3, 6, 9 and 12 months
Change in central macular thickness
Baseline and1，2， 3, 6, 9 and 12 months
Eligibility Criteria
Chinese
You may qualify if:
- Male or female aged 18 years or more
- Patients with a diagnosis of CRVO,BRVO or HRVO without macular edema
- Duration of RVO not more than 4 months
- Patient who agrees to participate to the study and who has given his/her written, informed consent
You may not qualify if:
- Patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period
- Active or suspected ocular or periocular infection
- Active severe intraocular inflammation
- RVO complicated with neovascularization
- Patient who has previously undergone laser panretinal photocoagulation, grid-laser or photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study eye
- Patient already included in the study for the treatment of the fellow eye
- Pregnant or breastfeeding woman
- Lack of effective contraception for women of childbearing age
- Patient taking part in an interventional study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Renmin Hospital of Wuhan University
Wuhan, Hubei, 430000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Renmin Hospital of Wuhan University
Renmin Hospital of Wuhan University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief of Department of Ophthalmology
Study Record Dates
First Submitted
August 29, 2019
First Posted
September 3, 2019
Study Start
September 18, 2019
Primary Completion
December 12, 2024
Study Completion
August 12, 2025
Last Updated
October 18, 2023
Record last verified: 2023-10